• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Trans-(±)-2,5-optionally substituted-octahydrothiazolo [4,5-g]quinolines, or their enantiomers, or their pharmaceutically-acceptable acid addition or quaternary salts thereof, are useful as dopamine agonists. They have the formula wherein R is H, benzyl, methyl, ethyl, n-propyl or allyl; R1is H, OH, halogen, methyl, HN2, NHC1-3 alkyl, N(C1-3 alkyl)2, 1-pyrrolidinyl, NHCOC1-3 alkyl, or NHC1-2 alkylphenyl; or a pharmaceutically-acceptable acid addition salt thereof.
    公开号:SU1414318A3
    申请号:SU853883101
    申请日:1985-04-22
    公开日:1988-07-30
    发明作者:Даниэль Титус Роберт；Карл Корнфельд Эдмунд
    申请人:Эли Лилли Энд Компани (Фирма)；
    IPC主号:
    专利说明:

    four
    09
    with

    cm
    The invention relates to a method for producing new trans - (+) - racemate, or trans (-), or trans (+) - enantiomers - quinoline derivatives, used as inhibitors of disorders (anxiety or depression) or as antihypertensive agents
    The purpose of the invention is to obtain new quinoline derivatives having improved compared with anal: with properties.
    Example 1. Getting trans- - (+) - 2-amino-5-n-prop 1-4.4 a, 5,6,7,8 8a-9-octahydrothiazolo (4,5-g) xinolin
    5 g of trans- (±) -1-n-propyl-6-oxo-decahydroquinoline was dissolved in 30 ml of glacial acetic acid, 5.8 ml of a solution of 37 wt% of hydrogen bromide in glacial acetic acid was added, and then dropwise m - 1.5 ml of bromine dissolved in glacial acetic acid. The reaction mixture was irradiated with ultraviolet rays (quartz lamps). The irradiated reaction mixture was stirred for 30 minutes. The easily evaporated components were removed from the reaction mixture in vacuo and obtained as a residue trans-(±) -1-c-propyl-6-ocean-7-bromo-dehydro-quinoline-hydrobromide. 0.01 mol of this salt was dissolved in 50 ml of ethanol. Then added to the solution of thiourea. The resulting mixture was refluxed for 18 hours under a nitrogen jacket. After about 20 minutes, a solid colorless precipitate began to form, the reaction mixture was cooled to 0 ° C, and the solid which continued to form was separated by filtration. The pressed precipitate was dried in vacuo. 0.15 g of trans - (+) - -2-amino-5-n-propyl-4,4a, 5,6,7,8, Za, 9-octahydrothiosol (4,5-e) quinoline indium bromohydrate, m.p. , TLC (9g, D chloroform: methanol + traces of ammonium hydroxide). Rf 0.13 "
    Calculated,%: C 38.02; H,; N 10.30; S 7.78.
    Found,%: C 37.79; H 5.61; N 10.17; S 7.76.
    The salt obtained in the manner described above was converted into freedoms by standard methods (e base, using aqueous ammonium hydroxide. The resulting free precipitates were crystallized, mp. With decomposition. 150 mg of free base logo was dissolved in methanol. Added



    N
    N

    2.98 ml of 0.2 M aqueous hydrochloric acid (1 eq.) And the resulting mixture was heated in a steam bath. The vapor of the components was removed in vacuo and the residue, trans- (+) 2-amino-5-n-propyl-4,43,5,6,7,8,8a, octohydrozolo hydrochloride (4,5-g ) xinolina has m.p., higher than 240 ° C after recrystallization from anhydrous ethanol. Calculated,%: C 54.23, H 7.70;
    14.60; C1 12.32; Found: C 54.52; H 7.91 -
    14.43; C1 t2,56.
    Trans - {+) - 2-amino-5-H-PROPIL-4,4a, 5,6,7,8,8a, 9-octa hydrothiazolo (4,5-g) quinoline dihydrochloride was prepared by dissolving 1 g of the free base in methanol, saturating the solution with gaseous hydrogen chloride and adding diethyl ether to the solution at the moment the precipitation begins. After cooling the crystallization mixture, crystals were obtained which were separated by filtration. The filtered precipitate was recrystallized first from a mixture of diethyl ether-ethanol and then / from ethanol alone. Got 0,65 salt, dihydrochloride, t, Sh1, 274 C (with decomposition).
    Calculated,%: C 48.15; H 7.15;
    12.96. Found,%: C 48.29; H 7.04;
    12.85.
    N
    0
    five
    20 - 30 35 40 45
    The described series of reactions was repeated with CIA of the starting material - 4aR, 8aR 1-n-propyl - 6-oxodecahydroquinoline. The ketone was alpha-brominated using the operation described and 4aK, 8aK-1-n-propyl-6-oxo-7-bromo-decahydroquinoline-hydrobromide was obtained, which, in turn, was reacted with thiourea in anhydrous ethanol, 2.4 g of colorless solid dibromo- rata was obtained from 1,, 01 g of thiourea, ibromohydrate was dissolved in water, and the free base was obtained in pure form by treatment with aqueous ammonium; yield 1.5 g. Using the described operation, the free base was converted into the hydrochloride. 1.08 g of 4aK, 8aK-2-amino-5-n-propyl-4,4a, 5, 6,7,8,8a, 9-octahydrothiazolo (4,5-g) - -quinoline hydrochloride was obtained with the following physical characteristics : TLC (9: 1 CHCIj / MeOH + traces) RfrrO, 58. . T, pl, above 225 ° C after recrystallization from ethanol. oi (water) -140,4 °,, 8.
    Calculated,%: C 54.24; H 7.70; N 14.60.
    .. Found,%: C 54.01; H 7.86; N 14.86.
    Example 2. Getting trans- (i) -2-methylamino-5-n-propyl-4,4a, 5,6,7,8,8a, 9-octahydrothiazolo (4,5-g) - quinoline.
    According to the method of Example 1, trans - (+) - -1-n-propyl-oxy-7-boro adhydroquinoline was brought into contact with N-methylthiourea in ethanol. The reaction mixture was heated to reflux. The solid began to appear after 5 hours of reflux. Heating of the reaction mixture to reflux continued for 18 hours. Then the reaction mixture was cooled to ambient temperature. The precipitated solid (colorless was separated by filtration, the pressed precipitate was dissolved in water and excess aqueous ammonium hydroxide was added to the solution. The alkaline solution was extracted with chloroform. Chloroform. The extract was removed, chloroform was removed in vacuo and 1.14 g were obtained (from 0.01 mol of the original material) trans () 2-methylamino-5-n-prop-1-4.4a, 5,6,7,8,8a, 9-octahydrothiazolo (4,5-g) quinoline. This compound was separated by chromatography over Florisil using as eluent chloroform containing excess (0-5%) methanol. Fractions containing more rapidly About stirring material, collected and obtained 0.7 g of a colorless solid. The solid was dissolved in methanol and the methanol solution was saturated with gaseous hydrogen chloride. At the moment of the start of precipitation, ether was added to the solution and the mixture was cooled rapidly. Thus obtained 0.34 g of crystalline dichlorohydrate trans- (±) -2-metsh1amino-5-N-PROPIL-4,4a, 5,6,7,8,8a, 9-octahydrothiazolo (4, 5-g) quinoline, so pl.
    Calculated,%: C 49.85, H 7.17, N 12.46; C1.
    Found,%: C 49.71; H 7.22; N 12.31; C1 20.87.
    Following the procedure of Example 1, but replacing thiourea with benzyl thiourea, trans - (+) - 2-benzylamino-5-H-7PROPIL-4, 4a, 5,6,7,8,8a, 9-octa4143 were obtained.
    -
    -. ) - - -
    ten
    15
    20
    25
    thirty
    35
    401
    45
    50
    55
    18 . . .
    hydrotiazolo (4,5-§) quinoline. This compound was purified by florisil chromatography using chloroform as eluent. Got the dihydrochloride salt. This salt was collected, dissolved in water and added excess alkali. The free base was extracted with chloroform, then the chloroform was evaporated in BajjyyMe and the free base was obtained in the residue. Then, a salt (maleate) was obtained in an ethanol solution, it was recrystallized from an ethanol – ether mixture of solvents, and trans-(+) - 2-benzylamino-5-n-propyl-4,4a maleate was obtained, 5,6,7,8 , 8a, 9-octahydrothiazolo (4, 5-g) quinoline. Yield: 0.17 g (out of 10.2 mmol trans- (±) -1-n-propyl-6-oxy-7-bromdecahydroquinoline), m.p. 210 s and under TLC gives a separate spot when using the solvents mentioned in example 1.
    Calculated,%: C 63.00; H 6.83, N 9.18.
    Found,%: C 63.22; H 6.99; N 8.95.
    In the case when R is C, -alkylphenyl, the compounds are prepared in an analogous manner.
    According to the procedure described in Example 1, 25.6 mmol of the track - (+) - n-propyl-6-oxo-7-bromodecahydroquinoline was reacted with a solution of L, H-dimethylthiourea in ethanol. As a result, the free base of trans- (+) -2-d№1ethylamino-5-n-yl) o-pil-4,4a, 5,6,7,8,8a, 9-octahydrothiazolo (4, 5-g ) quinoline as a yellow viscous oil. This oil was dissolved in methanol and the resulting solution was saturated with gaseous hydrogen chloride. At the start of precipitation, diethyl ether was added to the solution and the mixture was cooled rapidly. As a result, 1.25 g of a colorless solid was obtained containing trans- (|) -2-dimethyl 1-t-but-5-n-propyl-4.4a, 5,6,7,8,8a, 9-octa dihydrochloride - Hydrothiazole (4,5-g) xinoline, so pl. above . ..
    Calculated,%: C 51.13; n 7.72; N 11.93; C1 20.12.
    Found,%: C N 7.46, N 11.78; C1 19J83. .
    Example 3. Obtaining trans- - (+) - 2 methyl-5-n-propyl-A, 4a, 5,6,7,8, 8a, 9-octahydrothiazolo (4,5-g) quinoline.
    A solution was prepared from 0.01 M trans-(+) - 1-n-propyl-6-oxo-7-bromo-decahydroquinoline bromohydrate and 35 mp of anhydrous ethanol, 0.83 g of thioacetamide was added to the mixture c. And heated for 18 hours her at reflux temperature. Then the reaction mixture was cooled and poured into water. The aqueous mixture was basified with a concentrated aqueous solution of ammonium hydroxide. The alkali-insoluble substances were extracted several times with chloroform. The extracts were combined and thoroughly washed with water and a saturated aqueous solution of sodium chloride, after which they were dried. PacT-j believe it was aryn in vacuum and a residue was obtained, which was then dissolved in chloroform, a solution of chromatographic chromatography on florisil, using chloroform as eluent. Fractions 20 that according to TLC contained the resulting trans - (+) - 2-methyl 5-n-propyl-4.4a, 5,6,7,8,8a, 9-octahydrothiazo (4.5- G) quinoline, collected, the solvent evaporated in vacuo. The residue 25 was dissolved in methanol and the resulting solution was saturated with gaseous hydrogen chloride. The methanol solution was discolored with activated charcoal and filtered. 0 At the start of precipitation, diethyl ether was added to the filtrate, thus obtained dichloro-par trans- (f) -2-n-proyl A, 4a, 5,6,7- 8,8a, 9-octahydrothiazolo (4,5 -g) quinoline recrystallized from water eta-, nola to obtain 0.11 g of a colorless solid salt, m.p. more than 225 C, f (9: 1 CHClj / MeOH —f trace of an aqueous solution of acgmonium hydroxide) 0.9. Q
    Calculated,%: C 52.01; H 7.48j N 8.66.
    Found,%: C, 51.98; H 7.26, N 8.77.
    EXAMPLE 5 Preparation of trans-j - (±) -2-amino-4,4a, 5,6,7,8,8a, 9-octahydrothiazolo (4, 5-g) quinoline.
    4 g of trans - (+) - 1-cyano-6-oxodec-hydroquinoline prepared according to the procedure described in Example 1, the solvents in 20 ml of chloroform, and a solution of 1.44 ml of chloroform solution was added to the solution of the solution. The reaction mixture was subjected to radiation using a mountain sun lamp, to-as in Example 1. During the reaction, a colorless solid substance was formed. After all the bromine has been added and the solution has been lost. To color, the solvent
    drove off in a vacuum. The residue containing trans- (±) -1-cyano-6-oxo-7- -bromodecahydroquinoline, according to mass spectrometry, showed M 256, This compound was used without further purification.
    According to the procedure described in Example 1.22.5 mmol of trans- (±) -1-cyan, o-6-oxo-7-bromodecahydroquinoline was dissolved in 50 ml of ethanol and 28.1 mmol of thiourea were added to the mixture. As a result of the reaction, a product was obtained which was isolated by the procedure described in Example 1. During the formation of the thiazole ring, 1 eq. BUT and 1 eq, HBg, which create a sufficiently acidic medium for the hydrolysis reaction of N-cyano groups. Thus obtained trans- (±) -2- -amino-4,4a, 5,6,7,8,8a, 9-octahydrothiazolo (4, 5-g) quinoline according to mass spectrographs had M -209, output 0 , 6 g. The free base was triturated with acetone and obtained 0.15 g of a solid substance with so pl. higher than 215 ° C.
    Calculated,%: C 57.38; H.7.22, N 20.08,
     Found,%: C 57.61; H 7, 46 N 19.8
    Example 5, Preparation of trans- (i) -2-amino-5-methyl-4 54a, 5,6,7,8- 8a, 9-octahydrothiazolo (4,5-g) quinoline ..
    2 g of trans - (+) - 6-oxadecahydroquinoline was dissolved in 75 ml of acetone, and 2.71 g of potassium carbonate and 0.9 ml of methyl iodide were added to the mixture. The reaction mixture was stirred at reflux for 2 days, then cooled to room temperature and diluted with water. The aqueous mixture was extracted with chloroform-isopropanol 3: 1. The extracts were combined, washed with a saturated aqueous solution of sodium chloride and dried. The solvent was distilled off in vacuum to obtain 1.8 g of a yellow oil containing trans - (+) - 1-methyl-b-oxo-decahydroquinoline. This oil was dissolved in chloroform and the chromate solution - grafted on florisil using chloroform containing increasing amounts (0-4%) of methanol as eluent. The fractions which, according to TLC, contained an 11-methyl derivative, were collected and obtained 1.6 g (yield 73.1 of a colorless viscous oil containing trans- (t) -methyl-6-oxadecahydol
    714
    Rohinolin, M 167, according to TLC, one point.
    The indicated compound (1.6 g) was dissolved in 20 ml of glacial acetic acid. 2.3 ml of a 31% solution of hydrogen bromide in glacial acetic acid was added to the mixture, after which a solution of 0.8 ml of bromine in 5 ml of acetic acid was added dropwise to the mixture. The reaction mixture was stirred at ambient temperature under ultraviolet irradiation for 0.5 h, after which the solvent was distilled off in vacuum, as a result of which trans- (±) -1-methyl-6-hydroxy-7-bromohydride Cahydroquinoline.
    About 10.8 mmol of the indicated hydrobromide was dissolved in 30 ml of anhydrous ethanol, to which 1.03 thio urea was added. The reaction was carried out and the product was isolated according to the procedure described in Example 1. Trans- (±) - -2-amino-5-methyl-4,4a dibromide, 5,6,7,8, 3,1-octahydrothiazolo (4 , 5-g) quinoline, thus obtained, was subjected to crystallization from methanol twice and 0.61 g of a colorless crystalline solid was obtained with mp. above 235 C. According to TLC, using chloroform-methanol 4: 1 with traces of an aqueous solution of ammonium hydroxide as a solvent, one stain was obtained, Rf 0.30.
    Calculated,%: C 34.30; H 4.97; N 10.91; Br 41.49.
    Found,%: C 34.58; H 5.2K N 10.67; Br 41.30.
    PRI me R 6. Getting 4aS, 8aS- -2-amino-5-n-prop1-4,4a, 5,6,7,8, Over, - 9-octahydrothiazolo (3,4-g) quinoline .
    A solution was prepared from 1.95 g of 4aS, 8a8-1-n-propyl-6-oxo-decahydroquinoline in 25 ml of glacial acetic acid. Under irradiation, 2.3 ml of a 31% aqueous solution of hydrogen bromide in glacial acetic acid and a solution of 0.6 ml of bromine in 5 ml of glacial acetic acid were added dropwise to the solution. The color of bromine disappeared immediately. After the addition was complete, the reaction mixture was stirred for 0.5 hours at ambient temperature, at which time the solvent was distilled off in vacuo. The resulting viscosity as a residue is a viscous orange substance containing

    0 5 o
    Q
    5 Q
    five
    eight
    4aS, 8a5-1-n-propyl-6-oxo-7-bromo decacahydroquinoline dibromohydrate was used without further purification.
    The orange residue was dissolved in 30 ml of anhydrous ethanol and 0.84 g of thiourea was added to the solution. The reaction mixture was heated at reflux for 20 hours, after which it was cooled and the resulting solid was separated by filtration. The filter cake was washed with ethanol and diethyl ether and then dried. After recrystallization of the filtered precipitate from methanol-diethyl ether mixture, 1.17 g of 4aS colorless crystalline dibromohydrate, 8a3-2-amino-5-n-propyl-4,4a, 5,6, - - 7 5 8,8ae were obtained. 9-octahydrothiazolo (3,4-g) quinoline with so pl. above 200 C, according to mass spectrographic data M) 23 in (water) + 88.4 °; Mf, j (water) + 312.8 °; The UV spectrum (ethanol) has maxima at a wavelength of 262 nm (5725.9), 326 nm (58.8).
    Calculated,%: C 37.79; H 5.61; N 10.17 ..
    Found,%: C 37.70; H 5.81; N 10.13.
    4aR, 8aK-1-substituted-6-oxodec7. hydroquinoline. used to prepare the starting 7-bromo compound described in Example 1.: Example. Using the procedure of the examples given, trans- (t) -5-n-propyl-4,4a, 5, b57, B, - 8a, 9-octahydrothiazolo (4,5-g) quinoline was obtained, which was separated by chromatography Florisil, using increasing chloroform, amounts (0-2%) of methanol as eluent. The fractions containing the desired product were combined, the combined fractions were re-separated by chromatography and a dark orange-red transparent oil was obtained. According to the NMR spectrum, this oil contains: about 53% of the desired product in the form of a free base; , 70. This oil was then re-separated by chromatography over the main bleach using chloroform containing 2% methanol as eluent. The fractions containing trans- (±) -5-n-propyl-4,4a, 5,6,7,8, Za, 91-octahydrothiazolo (4,5-g) quinoline, were combined and the solvent was evaporated. Received the target product in the form of dichlorohydrate. M.p. 240 ° C .;
    Calculated,%: C 50.48; H 7.17; N 9.09.
    Found,%: C 50.69; H 6.87, N 9.18.
    Mass spectrum of M 236. Metiodide, Nuk1 salt of trans - (+) - 5-n- -propyl-A, 4a, 5,6,7,8,8a, 9-octagidothiazole (4,) quinoline obtained from 0 , 22 g of free base in ace; toner, to which 15 ml of methyl iodide was added, the reaction mixture was refluxed overnight, and then cooled to room temperature, the solid substance containing trans- (±) 5-n-propi-4, 4a, 5,6,7,8,8a, 9.- -octahydrothiazolo (A, 5-g) -quinoline-thiodide hydro-iodide was separated by filter-: sy and the dried residue was dried. Exit 0.2 g, m.p. above 225 ° C. Mass spectrum M 251.
    Calculated,%: C 33.32; H 4.78; N 5.58.
    Found%: C 33.42; H 4.57; N.5..50. .
    : Biological test data. : Adult rats of a male specimen of the species ISprague-Dawley weighing 200 g were kept in a room with air conditioning and (adjustable lighting (lit from 16:00 am to 8:00 pm), fed and Ipili on demand. Each rat was injected intraperitoneally with a solution of 2.0 mg reperpine in an aqueous suspension 18 hours prior to the administration of the test drug. Reserpine was administered to ensure a uniform increase in the level of prolactin. The compound was dissolved in 10% ethanol and administered intraperitoneally in doses of 0.017, 0.03, 0.17 and 0 , 3 µmol / kg. The compound was administered in a cadda dose to a group of 10 rats, and control group of 10 fitment administered an equivalent amount of 10% -ttoro ethanol. After 1 h after insertion is all rats preparations dekapiti- Rowan and 150 .mu.l aliquots of serum were assayed for prolactin.
    By dividing the difference between the level of prolactin In the treated rats and the level of prolactin in the control rats by the level of prolactin in the control rats, a decrease in the secretion of prolactin at a given dose (%) was determined
    The results of the experiments i. shown in table 1.1
    The compounds obtained by the proposed method also show their activity when administered in the mouth, but in large doses.
    It was also found that the proposed compounds, dopamine D-2 agonists, had an effect on twitching in rats that had been administered 6-rxid opamine, in tests aimed at identifying drugs useful in parkinsonism treatment. A compound with dopamine agonist activity causes the rats to rotate to the opposite side to which the drug was administered. After the latent period, which varies depending on the connection, the number of turns in 15 minutes was calculated.
    The results are shown in table 2.
    The compounds prepared according to the proposed method are effective for the treatment of hypertension. These compounds show this activity in standard laboratory tests, namely when administered to rats in which the pressure spontaneously rises, or in blocking norepinephrine released from sympathetic nerve endings in clogged rats in which the pressure spontaneously increased. These compounds exhibit insufficient alpha-adrenaline blocking activity.
    Activity when affecting the sexual function of the proposed compounds was determined by measuring the latency on caking, the latency of the introsium, the latency of the ejaculation, the post-ejection interval, the frequency and the frequency of the intromission in male rats that need at least five months. to achieve ejection when a sexually susceptible female is brought to them before the drug is administered. A decrease in one or more of these factors indicates a positive effect on sexual function in mammals (males), including an improvement in potency, but not limited to them. Sexually passive male rats can also be used in these tests.
    Positive effect on sexual function in mammals females
    1114
    is detected when the compounds are administered to female rats with estrogen-treated ovaries removed, and the ratio of lordosis to cage is determined. The increase in this value indicates that a positive effect should be expected in female mammals suffering from sexual disorders.
    The activity of compounds that are dopamine D-1 agonists was determined by their ability to stimulate the formation of cyclic AMP in the membranes of striped tissues in rats or increased the outflow of cyclic AMP in sections of striped tissues.
    To treat sexual disorders, improve potency, decrease blood pressure (through D-2 or D-1 mechanism) 5 to increase renal vascular flow, to treat depression or anxiety, to alleviate Parkinson's disease, or to reduce prolactin secretion, oral tablets, capsules or suspensions containing 0.1–2 mg of the active substance per dose, 3-4 times a day, daily dose 0, 8 mg. When administered internally, the doses are 0.1-100 µg / kg.
    Table 3 shows the activity of LYI 63792 and their enantiomers in tests for dopaminergic activity both in vivo and in vitro. According to their activity in the test for inhibition of prolactin LY163792, they are almost equivalent to pergolide. The specificity of these compounds is emphasized by the fact that 4TOj shows good activity with respect to dopamine receptors, their activity with respect to vab, s, 5HT, and 5HT receptors is negligible (data not shown).
    From Table 3 it can be seen that the activity of these partial Ergolins of the BSO-type is stereospecific, and the levorotatory antipode is responsible for all the activity of the racemate. In each case, the absolute configuration of the active anti8 2
    the hearth coincides with the natural ergolin configuration.
    LYI 63792 et al. Are new selective members of the BCD-type dopaminergic incomplete ergolins. As with representatives of other dopaminergic classes, their activity is stereospecific.
    In addition, it was found that in the active test dose of the compound obtained by the proposed method, showed no signs of toxicity, none of the experimental animals died.
    权利要求:
    Claims (1)
    [1]
    Invention Formula
    The method of obtaining trans (±) - racemate, or trans - (-) -, or trans - (+) - - enantiomer - quinoline derivatives
    general formula
    )
    BUT
    gI
    where -Cj-Cj is alkyl with a straight chain hydrogen, methyl, amino group W1 (C, -C, -alkyl), H (C, -C5-alkyl) or W (C, -C-alkyl. phenyl
    or their pharmaceutically acceptable acid addition salts, in which the compound of the general formula
    where R, has the specified value, is subjected to interaction with the compound,
    SH,
    where R has the indicated meanings, with the desired product being isolated in free form or in the form of a pharmaceutically acceptable acid addition salt.


    NH,
    SHSN,
    H (CH,) NH NH Benzyl
    1 -Pyrrole-) 1aleate dinyl
    NH-CO-CH, Free OcHQiaibie
    trans - (-) trans- (±)
    about
    P
    H
    NN,
    H
    he
    2HS1 2NVg
    HI Methoiodide - V CH1 - RjfC
    H-np
    NH,
    2SBie
    trans (i)
     NHCH
    2HC1
    -
    Table 1
    69
    67
    35
    14
    Table
    X9
    B,
    78 O
    100 100
    51
    100 80
    15
    Vg
    trans- (±)
     Inhibition of prolactin in male rats with the introduction of reserpine. The dosage at which the level of prolactin is reduced by 50% compared with the control.
    1414318
    sixteen
    Please see table 2
    1000
    100
    42
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1414318A3|1988-07-30|Method of producing trans-|-racemate or trans|- or trans|- enanthiomer-derivatives of quinoline or their pharmaceutically acceptable salts
    RU2119921C1|1998-10-10|Derivatives of camptothecine, methods of synthesis, compounds, pharmaceutical composition
    US4675319A|1987-06-23|Antianaphylactic and antibronchospastic piperazinyl-|carboxamides, compositions and use
    BRPI0610308A2|2010-11-09|compositions and methods for the treatment of retinal disease
    SU1597096A3|1990-09-30|Method of producing derivatives of diphenylpropyl amine or their pharmaceutically acceptable salts
    US20080280941A1|2008-11-13|8-Phenoxy-Gamma Carboline Derivatives
    HU180045B|1983-01-28|Process for producing new amino-thiasole derivatives
    EP0005828A1|1979-12-12|New substituted phenylpiperazine derivatives, pharmaceutical compositions containing them and process for their preparation
    SU1342415A3|1987-09-30|Method of producing derivatives of pyridazine
    HU195486B|1988-05-30|Process for preparing new pyridine derivatives
    US4134991A|1979-01-16|Derivatives of 2-|-acetic acid
    US3632587A|1972-01-04|Piperazino methyl isatinylidine 3 acetates
    US4492709A|1985-01-08|2-[4|-Amino-3|-hydroxyphenylimino]-imidazolines, useful in the treatment of gastric hypersecretion and hyperacidity
    US4507478A|1985-03-26|2-Mercaptopyrimidohexahydroquinolines and related compounds
    AU641394B2|1993-09-23|Amines
    SU816403A3|1981-03-23|Method of preparing 4-amino-2-|-or 4-amino-2-|qui
    EP0012822B1|1982-12-01|3,4-disubstituted 2-phenylimino-imidazolidines, their acid addition salts, pharmaceutical preparations containing them and process for their production
    EP0050072B1|1984-12-27|Cyclopropyl methyl piperazines, process for their preparation and their use in therapeutics
    EP0143461B1|1989-09-06|Rhodanine derivative, process for preparing the same and pharmaceutical composition containing the same
    US4338319A|1982-07-06|Method for the treatment of chronic obstructive airway or cardiac diseases
    CA1095914A|1981-02-17|4-hydroxy-2-quinolinone-3-carboxylic acid compounds
    EP0139393B1|1991-05-15|Pyrimido|quinolines, process for their preparation, and pharmaceutical compositions containing them
    KR840000605B1|1984-04-28|Process for the preparation of 2-amino-3-|phenylacetic acids
    RU2298010C2|2007-04-27|DERIVATIVES OF DIHYDROIMIDAZO[5,1-A]-β-CARBOLINE, METHOD FOR THEIR PREPARING AND PHARMACEUTICAL COMPOSITION
    BR112012022349B1|2019-09-24|COMPOUND, METHOD FOR TREATING A DISEASE, AND PROCESS
    同族专利:
    公开号 | 公开日
    ZA852999B|1986-11-26|
    NZ211863A|1987-10-30|
    EP0160502B1|1991-09-25|
    JPH0631262B2|1994-04-27|
    GR850989B|1985-11-25|
    ES8704177A1|1987-03-16|
    US4537893A|1985-08-27|
    EP0160502A3|1987-03-11|
    PT80339B|1987-02-16|
    KR850007261A|1985-12-02|
    DK185485D0|1985-04-25|
    JPS60233091A|1985-11-19|
    KR870001072B1|1987-05-27|
    HU193113B|1987-08-28|
    EP0160502A2|1985-11-06|
    ES542565A0|1987-03-16|
    PT80339A|1985-05-01|
    IL74988D0|1985-08-30|
    HUT37624A|1986-01-23|
    PH21951A|1988-04-15|
    AU564946B2|1987-09-03|
    AU4166685A|1985-10-31|
    DE3584183D1|1991-10-31|
    DK185485A|1985-10-28|
    CA1287356C|1991-08-06|
    AT67767T|1991-10-15|
    CN85101547A|1987-01-24|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    RU2573399C2|2011-03-14|2016-01-20|Киссеи Фармасьютикал Ко., Лтд.|New octahydrothienoquinoline derivative, pharmaceutical composition containing derivative, and using them|DE2056224A1|1969-11-17|1971-06-03|Danchi Seiyaku Co , Ltd , Tokio|New Thiazolochinohnderivate and Ver drive for their production|
    US4367231A|1979-09-14|1983-01-04|Eli Lilly And Company|Method of using octahydro pyrazolo[3,4-g]quinolines|
    US4198415A|1979-01-22|1980-04-15|Eli Lilly And Company|Prolactin inhibiting octahydro pyrazolo[3,4-g]quinolines|
    US4258049A|1979-07-02|1981-03-24|Smithkline Corporation|Inhibiting phenylethanolamine N-methyltransferase with thiadiazolo and oxadiazolotetrahydroisoquinolines|US4778894A|1983-09-26|1988-10-18|Eli Lilly And Company|6 oxo-decahydroquinolines|
    US4826986A|1986-06-16|1989-05-02|Eli Lilly And Company|6-Oxo-trans-octa- and decahydroquinolines|
    US5134143A|1986-06-16|1992-07-28|Eli Lilly And Company|BCD tricyclic ergoline part-structure analogues|
    US4977160A|1986-06-16|1990-12-11|Eli Lilly And Company|BCD tricyclic ergoline part-structure analogues|
    DE3624607A1|1986-07-21|1988-01-28|Boehringer Ingelheim Kg|NEW TETRAHYDROBENZOTHIAZOLO-CHINOLINE THEIR PRODUCTION AND USE|
    US4762843A|1986-09-15|1988-08-09|Warner-Lambert Company|Hetero [f] fused carbocyclic pyridines as dopaminergic agents|
    US4939259A|1989-07-24|1990-07-03|Eli Lilly And Company|2-oxo-pyrido[2,3-g]quinoline derivatives|
    US4977149A|1989-07-24|1990-12-11|Eli Lilly And Company|Pyridoquinoline dopamine agonists, compositions and use|
    US5006525A|1989-07-24|1991-04-09|Eli Lilly And Company|Dopamine agonists method|
    US5057515A|1989-07-24|1991-10-15|Eli Lilly And Company|Method for agonizing a dopamine receptor|
    US5416090A|1991-01-31|1995-05-16|Eli Lilly And Company|Method of treating inflammation|
    EP0816406B1|1996-06-26|2000-09-06|Bayer Ag|Process for preparation of essentially salt free condensation products|
    WO2009139855A2|2008-05-14|2009-11-19|Ipsen Pharma S.A.S.|Pharmaceutical compositions of somatostatin-dopamine conjugates|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    US06/604,687|US4537893A|1984-04-27|1984-04-27|Octahydrothiazolo[4,5-g]quinolines and use as prolactin secretion inhibitors|
    [返回顶部]